Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | LY6K | Q17RY6 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974776 | 0.83 | PKM (0.49) | PKMFLT1FLT4KDROPRM1 | |
| SCHEMBL24974545 | 0.82 | PKM (0.46) | PKMFLT1FLT4KDROPRM1 | |
| SCHEMBL24974540 | 0.80 | PKM (0.47) | PKMFLT1FLT4KDROPRM1 | |
| SCHEMBL24974633 | 0.78 | PKM (0.47) | PKMFLT1FLT4KDROPRM1 | |
| SCHEMBL24974369 | 0.78 | USP2 (0.47) | — | |
| SCHEMBL24974743 | 0.76 | OPRM1 (0.48) | PKMOPRM1KEAP1CA12CA1 | |
| SCHEMBL24974781 | 0.75 | SIRT2 (0.48) | PKMOPRM1KEAP1CA12CA1 | |
| SCHEMBL24974546 | 0.75 | ITGB1 (0.39) | PKMKEAP1HTR6CA12CA1 | |
| SCHEMBL24974638 | 0.73 | PKM (0.47) | PKMFLT1FLT4KDROPRM1 | |
| SCHEMBL24974600 | 0.72 | GBA1 (0.50) | PKMOPRM1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | PKM 3656/4885FLT1 166/4885FLT4 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.